A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.

Antibodies, Monoclonal, Humanized/adverse effects,therapeutic use Antineoplastic Agents/adverse effects,therapeutic use Antineoplastic Combined Chemotherapy Protocols/adverse effects,therapeutic use Diabetes Mellitus, Type 1/diagnosis,etiology,therapy Disease Management Humans Insulins/administration & dosage,therapeutic use Male Melanoma/complications,diagnosis,drug therapy Middle Aged Molecular Targeted Therapy/adverse effects Patient Outcome Assessment Programmed Cell Death 1 Receptor/antagonists & inhibitors Skin Neoplasms Treatment Outcome

Antibodies, Monoclonal, Humanized Antineoplastic Agents Insulins Programmed Cell Death 1 Receptor pembrolizumab

Melanoma, Cutaneous Malignant (Disease)